{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:26:10Z","timestamp":1783470370622,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T00:00:00Z","timestamp":1470096000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Cancer Prevention Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12876-016-0494-4","type":"journal-article","created":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T22:02:33Z","timestamp":1470088953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Efficacy and safety of eflornithine (CPP-1X)\/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial"],"prefix":"10.1186","volume":"16","author":[{"given":"Carol A.","family":"Burke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Jewel","family":"Samadder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Stoffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,2]]},"reference":[{"key":"494_CR1","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1126\/science.1651562","volume":"253","author":"KW Kinzler","year":"1991","unstructured":"Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, et al. Identification of FAP locus genes from chromosome 5q21. Science. 1991;253:661\u20135.","journal-title":"Science"},{"key":"494_CR2","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/gut.2007.136127","volume":"57","author":"HF Vasen","year":"2008","unstructured":"Vasen HF, Moslein G, Alonso A, Aretz S, Bernstein I, Bertario L, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut. 2008;57:704\u201313.","journal-title":"Gut"},{"key":"494_CR3","doi-asserted-by":"publisher","first-page":"16620","DOI":"10.3748\/wjg.v20.i44.16620","volume":"20","author":"FG Campos","year":"2014","unstructured":"Campos FG. Surgical treatment of familial adenomatous polyposis: dilemmas and current recommendations. World J Gastroenterol. 2014;20:16620\u20139.","journal-title":"World J Gastroenterol"},{"key":"494_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4251\/wjgo.v7.i11.347","volume":"7","author":"I Jung","year":"2015","unstructured":"Jung I, Gurzu S, Turdean GS. Current status of familial gastrointestinal polyposis syndromes. World J Gastrointest Oncol. 2015;7:347\u201355.","journal-title":"World J Gastrointest Oncol"},{"key":"494_CR5","first-page":"95","volume":"8","author":"ML Leoz","year":"2015","unstructured":"Leoz ML, Carballal S, Moreira L, Ocana T, Balaguer F. The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management. Appl Clin Genet. 2015;8:95\u2013107.","journal-title":"Appl Clin Genet"},{"key":"494_CR6","first-page":"538","volume":"231","author":"L Bertario","year":"2000","unstructured":"Bertario L, Russo A, Radice P, Varesco L, Eboli M, Spinelli P, et al. Genotype and phenotype factors as determinants for rectal stump cancer in patients with familial adenomatous polyposis. Hereditary Colorectal Tumors Registry Ann Surg. 2000;231:538\u201343.","journal-title":"Hereditary Colorectal Tumors Registry Ann Surg"},{"key":"494_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1445-2197.1998.tb04724.x","volume":"68","author":"DC Jenner","year":"1998","unstructured":"Jenner DC, Levitt S. Rectal cancer following colectomy and ileorectal anastomosis for familial adenomatous polyposis. Aust N Z J Surg. 1998;68:136\u20138.","journal-title":"Aust N Z J Surg"},{"key":"494_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/00000658-200103000-00009","volume":"233","author":"YR Parc","year":"2001","unstructured":"Parc YR, Olschwang S, Desaint B, Schmitt G, Parc RG, Tiret E. Familial adenomatous polyposis: prevalence of adenomas in the ileal pouch after restorative proctocolectomy. Ann Surg. 2001;233:360\u20134.","journal-title":"Ann Surg"},{"key":"494_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/BF02234731","volume":"44","author":"MW Thompson-Fawcett","year":"2001","unstructured":"Thompson-Fawcett MW, Marcus VA, Redston M, Cohen Z, McLeod RS. Adenomatous polyps develop commonly in the ileal pouch of patients with familial adenomatous polyposis. Dis Colon Rectum. 2001;44:347\u201353.","journal-title":"Dis Colon Rectum"},{"key":"494_CR10","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/BF02235258","volume":"41","author":"JS Wu","year":"1998","unstructured":"Wu JS, McGannon EA, Church JM. Incidence of neoplastic polyps in the ileal pouch of patients with familial adenomatous polyposis after restorative proctocolectomy. Dis Colon Rectum. 1998;41:552\u20136. discussion 556-557.","journal-title":"Dis Colon Rectum"},{"key":"494_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/gut.2003.027771","volume":"53","author":"S Bulow","year":"2004","unstructured":"Bulow S, Bjork J, Christensen IJ, Fausa O, Jarvinen H, Moesgaard F, et al. Duodenal adenomatosis in familial adenomatous polyposis. Gut. 2004;53:381\u20136.","journal-title":"Gut"},{"key":"494_CR12","first-page":"199","volume":"57","author":"FM Giardiello","year":"1997","unstructured":"Giardiello FM, Hamilton SR, Hylind LM, Yang VW, Tamez P, Casero Jr RA. Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res. 1997;57:199\u2013201.","journal-title":"Cancer Res"},{"key":"494_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-3-642-10858-7_4","volume":"188","author":"N Babbar","year":"2011","unstructured":"Babbar N, Gerner EW. Targeting polyamines and inflammation for cancer prevention. Recent Results Cancer Res. 2011;188:49\u201364.","journal-title":"Recent Results Cancer Res"},{"issue":"Suppl 1","key":"494_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/01635580802401317","volume":"60","author":"NA Ignatenko","year":"2008","unstructured":"Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H, Gerner EW. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis. Nutr Cancer. 2008;60 Suppl 1:30\u20135.","journal-title":"Nutr Cancer"},{"key":"494_CR15","unstructured":"ClinicalTrials.gov: A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of CPP-1X\/Sulindac Compared With CPP-1X, Sulindac as Single Agents in Patients with Familial Adenomatous Polyposis (FAP), 2015."},{"key":"494_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"494_CR17","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/j.ejca.2009.08.014","volume":"45","author":"RN Whistance","year":"2009","unstructured":"Whistance RN, Conroy T, Chie W, Costantini A, Sezer O, Koller M, et al. Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. Eur J Cancer. 2009;45:3017\u201326.","journal-title":"Eur J Cancer"},{"key":"494_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53\u201372.","journal-title":"Health Policy"},{"key":"494_CR19","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"MF Drummond","year":"1997","unstructured":"Drummond MF, Sculpher MJ, Torrance GW, O\u2019Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press; 1997."},{"key":"494_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1037\/0278-6133.10.4.259","volume":"10","author":"C Lerman","year":"1991","unstructured":"Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A. Psychological side effects of breast cancer screening. Health Psychol. 1991;10:259\u201367.","journal-title":"Health Psychol"},{"key":"494_CR21","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Bethesda, MD: National Institutes of Health; 2010."},{"key":"494_CR22","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1002\/bjs.1800801244","volume":"80","author":"KP Nugent","year":"1993","unstructured":"Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993;80:1618\u20139.","journal-title":"Br J Surg"},{"key":"494_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s003840050071","volume":"12","author":"CS Richard","year":"1997","unstructured":"Richard CS, Berk T, Bapat BV, Haber G, Cohen Z, Gallinger S. Sulindac for periampullary polyps in FAP patients. Int J Colorectal Dis. 1997;12:14\u20138.","journal-title":"Int J Colorectal Dis"},{"key":"494_CR24","doi-asserted-by":"crossref","unstructured":"Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, et al. The effect of celecoxib, a cyclooxgenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946-52.","DOI":"10.1056\/NEJM200006293422603"},{"key":"494_CR25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/gutjnl-2014-307235","volume":"65","author":"PM Lynch","year":"2016","unstructured":"Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Wang X, et al. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut. 2016;65:286\u201395.","journal-title":"Gut"},{"key":"494_CR26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1200\/JCO.2004.06.028","volume":"22","author":"JC Saurin","year":"2004","unstructured":"Saurin JC, Gutknecht C, Napoleon B, Chavaillon A, Ecochard R, Scoazec JY, et al. Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol. 2004;22:493\u20138.","journal-title":"J Clin Oncol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-016-0494-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-016-0494-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-016-0494-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-016-0494-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T15:42:11Z","timestamp":1498318931000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-016-0494-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["494"],"URL":"https:\/\/doi.org\/10.1186\/s12876-016-0494-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,2]]},"article-number":"87"}}